Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2

被引:32
|
作者
Chuang, Yu-Hsuan [1 ]
Lill, Christina M. [6 ]
Lee, Pei-Chen [9 ]
Hansen, Johnni [10 ]
Lassen, Christina F. [10 ]
Bertram, Lars [7 ,8 ,11 ]
Greene, Naomi [1 ]
Sinsheimer, Janet S. [2 ,4 ]
Ritz, Beate [1 ,3 ,5 ]
机构
[1] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, 650 Charles E Young Dr, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Environm Hlth Sci, Los Angeles, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet & Biomathemat, Los Angeles, CA 90095 USA
[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
[6] Univ Lubeck, Inst Neurogenet, Genet & Mol Epidemiol Grp, Lubeck, Germany
[7] Univ Lubeck, Inst Neurogenet, Interdisciplinary Platform Genome Analyt LIGA, Lubeck, Germany
[8] Univ Lubeck, Inst Integrat & Expt Genom, Interdisciplinary Platform Genome Analyt LIGA, Lubeck, Germany
[9] Natl Taipei Univ Nursing Hlth Sci, Coll Healthcare Adm & Management, Dept Hlth Care Management, Taipei, Taiwan
[10] Danish Canc Soc, Res Ctr, Copenhagen, Denmark
[11] Imperial Coll Sci Technol & Med, Fac Med, Sch Publ Hlth, London, England
基金
美国国家卫生研究院;
关键词
Parkinson's disease; Caffeine; Adenosine A2A receptor (ADORA2A); Cytochrome P450 1A2 (CYP1A2); Meta-analysis; RECEPTOR INTERACTIONS; ADENOSINE RECEPTOR; CAFFEINE; RISK; ASSOCIATION; SMOKING; NEUROPROTECTION; POLYMORPHISMS; CONNECTION; MODEL;
D O I
10.1159/000450855
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background and Purpose: Drinking caffeinated coffee has been reported to provide protection against Parkinson's disease (PD). Caffeine is an adenosine A2A receptor (encoded by the gene ADORA2A) antagonist that increases dopaminergic neurotransmission and Cytochrome P450 1A2 (gene: CYP1A2) metabolizes caffeine; thus, gene polymorphisms in ADORA2A and CYP1A2 may influence the effect coffee consumption has on PD risk. Methods: In a population-based case-control study (PASIDA) in Denmark (1,556 PD patients and 1,606 birth year-and gender-matched controls), we assessed interactions between lifetime coffee consumption and 3 polymorphisms in ADORA2A and CYP1A2 for all subjects, and incident and prevalent PD cases separately using logistic regression models. We also conducted a meta-analysis combining our results with those from previous studies. Results: We estimated statistically significant interactions for ADORA2A rs5760423 and heavy vs. light coffee consumption in incident (OR interaction = 0.66 [95% CI 0.46-0.94], p = 0.02) but not prevalent PD. We did not observe interactions for CYP1A2 rs762551 and rs2472304 in incident or prevalent PD. In meta-analyses, PD associations with daily coffee consumption were strongest among carriers of variant alleles in both ADORA2A and CYP1A2. Conclusion: We corroborated results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our results also suggest that survivor bias may affect results of studies that enroll prevalent PD cases. (C) 2017 S. Karger AG, Basel
引用
收藏
页码:192 / 200
页数:9
相关论文
共 50 条
  • [1] Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease
    Popat, R. A.
    Van Den Eeden, S. K.
    Tanner, C. M.
    Kamel, F.
    Umbach, D. M.
    Marder, K.
    Mayeux, R.
    Ritz, B.
    Ross, G. W.
    Petrovitch, H.
    Topol, B.
    McGuire, V.
    Costello, S.
    Manthripragada, A. D.
    Southwick, A.
    Myers, R. M.
    Nelson, L. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (05) : 756 - 765
  • [2] ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson's Disease
    Siokas, Vasileios
    Aloizou, Athina-Maria
    Tsouris, Zisis
    Liampas, Ioannis
    Liakos, Panagiotis
    Calina, Daniela
    Docea, Anca Oana
    Tsatsakis, Aristidis
    Bogdanos, Dimitrios P.
    Hadjigeorgiou, Georgios M.
    Dardiotis, Efthimios
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (03) : 1 - 9
  • [3] An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's disease
    Hill-Burns, E. M.
    Hamza, T. H.
    Zabetian, C. P.
    Factor, S. A.
    Payami, H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (09) : E107 - E108
  • [4] Genetic Polymorphisms in ADORA2A and CYP1A2 Influence Caffeine's Effect on Postprandial Glycaemia
    Banks, N. F.
    Tomko, P. M.
    Colquhoun, R. J.
    Muddle, T. W. D.
    Emerson, S. R.
    Jenkins, N. D. M.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [5] The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson's Disease
    Ari, B. C.
    Domac, F. Mayda
    Kenangil, G. Ozgen
    Imamova, N.
    Kuskucu, A. Cinar
    MOVEMENT DISORDERS, 2019, 34 : S166 - S166
  • [6] Genetic Polymorphisms in ADORA2A and CYP1A2 Influence Caffeine’s Effect on Postprandial Glycaemia
    N. F. Banks
    P. M. Tomko
    R. J. Colquhoun
    T. W. D. Muddle
    S. R. Emerson
    N. D. M. Jenkins
    Scientific Reports, 9
  • [7] ADORA2A, but Not CYP1A2, Genotype Influences Caffeine's Effect On Glucose Responses To A Carbohydrate Feeding
    Banks, Nile
    Tomko, Patrick
    Colquhoun, Ryan
    Muddle, Tyler
    Magrini, Mitchel
    Emerson, Sam
    Jenkins, Nathaniel
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2019, 51 (06): : 716 - 716
  • [8] Gene-environment interaction in Parkinson's disease - The case of CYP2D6 gene polymorphism
    Landi, MT
    Ceroni, M
    Martignoni, E
    Bertazzi, PA
    Caporaso, NE
    Nappi, G
    PARKINSON'S DISEASE, 1996, 69 : 61 - 72
  • [9] Analysis of ADORA2A rs5760423 and CYP1A2 rs762551 Genetic Variants in Patients with Alzheimer's Disease
    Siokas, Vasileios
    Mouliou, Dimitra S.
    Liampas, Ioannis
    Aloizou, Athina-Maria
    Folia, Vasiliki
    Zoupa, Elli
    Papadimitriou, Anastasios
    Lavdas, Eleftherios
    Bogdanos, Dimitrios P.
    Dardiotis, Efthimios
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [10] Parkinson's disease and CYP1A2 activity
    Forsyth, JT
    Grünewald, RA
    Rostami-Hodjegan, A
    Lennard, MS
    Sagar, HJ
    Tucker, GT
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (04) : 303 - 309